Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00792688 · ClinicalTrials.gov registry record · Phase 2
Efficacy Study of GLYC-101 to Evaluate Outcomes After Laser Ablation
A Phase 2 study of Wounds, sponsored by TR Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT00792688: Completed Phase 2 study of Wounds, sponsored by TR Therapeutics.
NCT00792688 is a Phase 2 study of Wounds that has completed, run by TR Therapeutics. The registered enrollment target is 26 participants, below the 99-participant average among 6 other Wounds trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00792688, a Phase 2 study of Wounds, has completed, sponsored by TR Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objectives of this study are to evaluate safety and efficacy of topically applied Glucoprime gel (GLYC-101, 0.1% and GLYC-101, 1.0%) in promoting wound healing in cosmetic surgery patients undergoing Carbon Dioxide Laser Skin Resurfacing (CO2 LSR) of the lower eyelids. The study will observe the effects of the topical agent over the course of 1 month following the initial treatment.
Primary Outcome
Subjects were evaluated daily from the time of the laser procedure and initial application of test article until the subject's wounds reached 100% epithelialization. Efficacy was assessed based on the time to complete epithelialization in terms of the number of days from Day 1 (day of laser ablation) to the day on which complete epithelialization was observed.
Conditions Studied
Interventions
- DRUG GLYC-101 Gel (0.1%)
- DRUG GLYC-101 Gel (1.0%)
- DRUG GLYC-101 Placebo
Study Locations (1)
California
- CLINICAL TESTING CENTER of BEVERLY HILLS - Beverly Hills
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2008-10 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
What the finished NCT00792688 record still lists
NCT00792688 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 99-participant average among 6 other Wounds trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Wounds appearing as the primary indexed condition, and to 3 interventions - of which GLYC-101 Gel (0.1%) is the first listed.
NCT00792688 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00792688 about?
NCT00792688 is a clinical study titled "Efficacy Study of GLYC-101 to Evaluate Outcomes After Laser Ablation". The primary objectives of this study are to evaluate safety and efficacy of topically applied Glucoprime gel (GLYC-101, 0.1% and GLYC-101, 1.0%) in promoting wound healing in cosmetic surgery patients undergoing Carbon Dioxide Laser Skin Resurfacing (CO2 LSR) of the lower eyelids. The study will obs...
What is the current status of trial NCT00792688?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2008-10. Estimated completion is 2010-01.
What conditions does trial NCT00792688 study?
This clinical trial studies the following conditions: Wounds.
What interventions are being tested in trial NCT00792688?
The interventions under investigation include: GLYC-101 Gel (0.1%) (DRUG), GLYC-101 Gel (1.0%) (DRUG), GLYC-101 Placebo (DRUG).
Who is sponsoring clinical trial NCT00792688?
This trial is sponsored by TR Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00792688 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Wounds
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
4-aminopyridine for Skin Wound Healing
RECRUITING · Phase 2
-
A Clinical Investigation to Follow the Progress of Exuding Chronic Wounds Using Mepilex® Up as the Primary Dressing.
RECRUITING · NA
-
Tissue Repair Gel in Venous Leg Ulcers (US)
RECRUITING · Phase 3
-
A Clinical Investigation to Follow the Progress of Exuding Chronic Venous Leg Ulcers Using a Non-Bordered Foam Dressing
RECRUITING · NA
-
Octylseal Surgical Adhesive in General Surgery
COMPLETED · Phase 4
-
Platelets in Acute Wounds: A Pilot Study (PAWS)
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia